JB Chemicals & Pharmaceuticals Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
1715.00 +49.10 (2.95%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1655.1
Today’s High
1720
52 Week Low
1376.95
52 Week High
2029
1710.00 +42.95 (2.58%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1655.25
Today’s High
1722
52 Week Low
1371
52 Week High
2030
Key Metrics
- Market Cap (In Cr) 25889.23
- Beta 0.21
- Div. Yield (%) 0.73
- P/B 8.85
- TTM P/E 47.61
- Peg Ratio 6.84
- Sector P/E 31.15
- D/E 0.03
- Open Price 1667.1
- Prev Close 1665.9
JB Chemicals & Pharmaceuticals Analysis
Price Analysis
-
1 Week-6.34%
-
3 Months-14.19%
-
6 Month-6.01%
-
YTD2.61%
-
1 Year10.3%
Risk Meter
- 29% Low risk
- 29% Moderate risk
- 29% Balanced Risk
- 29% High risk
- 29% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 6
- 6
- 6
- 5
- Buy
- 2
- 2
- 2
- 2
- Hold
- 2
- 2
- 2
- 2
- Sell
- 1
- 1
- 0
- 0
- Strong Sell
- 0
- 0
- 1
- 1
- Total
- 11
- 11
- 11
- 10
JB Chemicals & Pharmaceuticals News
Axis Bank, Zomato & more: Kotak Securities lists 8 stock picks for Diwali 2024
6 min read . 22 Oct 2024JB Chemicals & Pharmaceuticals Q1 Results Live : profit rise by 24.25% YOY
1 min read . 09 Aug 2024JB Chemicals & Pharmaceuticals Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 3484.18
- Selling/ General/ Admin Expenses Total
- 601.41
- Depreciation/ Amortization
- 138.32
- Other Operating Expenses Total
- 803.83
- Total Operating Expense
- 2725.61
- Operating Income
- 758.57
- Net Income Before Taxes
- 751.51
- Net Income
- 552.63
- Diluted Normalized EPS
- 34.85
- Period
- 2024
- Total Assets
- 3994.13
- Total Liabilities
- 1070.8
- Total Equity
- 2923.33
- Tangible Book Valueper Share Common Eq
- 95.19
- Period
- 2024
- Cashfrom Operating Activities
- 800.62
- Cashfrom Investing Activities
- -403.83
- Cashfrom Financing Activities
- -385.48
- Net Changein Cash
- 11.29
- Period
- 2023
- Total Revenue
- 3149.28
- Selling/ General/ Admin Expenses Total
- 1093.9
- Depreciation/ Amortization
- 114.41
- Other Operating Expenses Total
- 72.2
- Total Operating Expense
- 2556.85
- Operating Income
- 592.43
- Net Income Before Taxes
- 555.23
- Net Income
- 409.84
- Diluted Normalized EPS
- 26.17
- Period
- 2023
- Total Assets
- 3553.87
- Total Liabilities
- 1073.52
- Total Equity
- 2480.35
- Tangible Book Valueper Share Common Eq
- 71.12
- Period
- 2023
- Cashfrom Operating Activities
- 625.61
- Cashfrom Investing Activities
- -961.79
- Cashfrom Financing Activities
- 356.54
- Net Changein Cash
- 20.39
- Period
- 2022
- Total Revenue
- 2424.24
- Selling/ General/ Admin Expenses Total
- 881.68
- Depreciation/ Amortization
- 72.66
- Other Operating Expenses Total
- 60.46
- Total Operating Expense
- 1949.65
- Operating Income
- 474.6
- Net Income Before Taxes
- 504.9
- Net Income
- 385.36
- Diluted Normalized EPS
- 24.79
- Period
- 2022
- Total Assets
- 2607.4
- Total Liabilities
- 473.28
- Total Equity
- 2134.12
- Tangible Book Valueper Share Common Eq
- 90.92
- Period
- 2022
- Cashfrom Operating Activities
- 170.13
- Cashfrom Investing Activities
- 2.32
- Cashfrom Financing Activities
- -138.39
- Net Changein Cash
- 34.07
- Period
- 2021
- Total Revenue
- 2042.52
- Selling/ General/ Admin Expenses Total
- 635.92
- Depreciation/ Amortization
- 68.67
- Other Operating Expenses Total
- 70.39
- Total Operating Expense
- 1555.01
- Operating Income
- 487.51
- Net Income Before Taxes
- 596.89
- Net Income
- 447.96
- Diluted Normalized EPS
- 26.43
- Period
- 2021
- Total Assets
- 2238.12
- Total Liabilities
- 428.39
- Total Equity
- 1809.72
- Tangible Book Valueper Share Common Eq
- 111.29
- Period
- 2021
- Cashfrom Operating Activities
- 314.78
- Cashfrom Investing Activities
- -230.68
- Cashfrom Financing Activities
- -87.42
- Net Changein Cash
- -3.28
- Period
- 2020
- Total Revenue
- 1774.73
- Selling/ General/ Admin Expenses Total
- 611.56
- Depreciation/ Amortization
- 66.32
- Other Operating Expenses Total
- 63.05
- Total Operating Expense
- 1466.74
- Operating Income
- 307.99
- Net Income Before Taxes
- 348.89
- Net Income
- 272.05
- Diluted Normalized EPS
- 17.39
- Period
- 2020
- Total Assets
- 1820.56
- Total Liabilities
- 385.07
- Total Equity
- 1435.49
- Tangible Book Valueper Share Common Eq
- 87.49
- Period
- 2020
- Cashfrom Operating Activities
- 275.75
- Cashfrom Investing Activities
- 23.93
- Cashfrom Financing Activities
- -306.05
- Net Changein Cash
- -6.39
- Period
- 2019
- Total Revenue
- 1643.2
- Selling/ General/ Admin Expenses Total
- 584.7
- Depreciation/ Amortization
- 55.64
- Other Operating Expenses Total
- 59.64
- Total Operating Expense
- 1384.58
- Operating Income
- 258.62
- Net Income Before Taxes
- 286.99
- Net Income
- 193.47
- Diluted Normalized EPS
- 11.67
- Period
- 2019
- Total Assets
- 1791.95
- Total Liabilities
- 311.83
- Total Equity
- 1480.12
- Tangible Book Valueper Share Common Eq
- 87.47
- Period
- 2019
- Cashfrom Operating Activities
- 193.08
- Cashfrom Investing Activities
- -26.89
- Cashfrom Financing Activities
- -155.29
- Net Changein Cash
- 10.9
- Period
- 2018
- Total Revenue
- 1414.3
- Selling/ General/ Admin Expenses Total
- 517.99
- Depreciation/ Amortization
- 56.97
- Other Operating Expenses Total
- 58.04
- Total Operating Expense
- 1252.99
- Operating Income
- 161.31
- Net Income Before Taxes
- 193.95
- Net Income
- 138.34
- Diluted Normalized EPS
- 8.16
- Period
- 2018
- Total Assets
- 1765.1
- Total Liabilities
- 323.55
- Total Equity
- 1441.56
- Tangible Book Valueper Share Common Eq
- 81.71
- Period
- 2018
- Cashfrom Operating Activities
- 122.92
- Cashfrom Investing Activities
- -20.68
- Cashfrom Financing Activities
- -59.52
- Net Changein Cash
- 42.72
- Period
- 2024-09-30
- Total Revenue
- 1000.62
- Selling/ General/ Admin Expenses Total
- 170.57
- Depreciation/ Amortization
- 41.88
- Other Operating Expenses Total
- 221.11
- Total Operating Expense
- 771.98
- Operating Income
- 228.64
- Net Income Before Taxes
- 236.53
- Net Income
- 174.57
- Diluted Normalized EPS
- 11
- Period
- 2024-09-30
- Total Assets
- 4029.41
- Total Liabilities
- 817.18
- Total Equity
- 3212.23
- Tangible Book Valueper Share Common Eq
- 115.66
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 377.63
- Cashfrom Investing Activities
- 9.57
- Cashfrom Financing Activities
- -385.54
- Net Changein Cash
- 1.67
- Period
- 2024-06-30
- Total Revenue
- 1004.4
- Selling/ General/ Admin Expenses Total
- 166.91
- Depreciation/ Amortization
- 40.78
- Other Operating Expenses Total
- 217.37
- Total Operating Expense
- 764.81
- Operating Income
- 239.59
- Net Income Before Taxes
- 239.84
- Net Income
- 176.83
- Diluted Normalized EPS
- 11.16
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 861.73
- Selling/ General/ Admin Expenses Total
- 152.7
- Depreciation/ Amortization
- 40.74
- Other Operating Expenses Total
- 210.63
- Total Operating Expense
- 704.35
- Operating Income
- 157.38
- Net Income Before Taxes
- 164.6
- Net Income
- 126.16
- Diluted Normalized EPS
- 8.06
- Period
- 2024-03-31
- Total Assets
- 3994.13
- Total Liabilities
- 1070.8
- Total Equity
- 2923.33
- Tangible Book Valueper Share Common Eq
- 95.19
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 800.62
- Cashfrom Investing Activities
- -403.83
- Cashfrom Financing Activities
- -385.48
- Net Changein Cash
- 11.29
- Period
- 2023-12-31
- Total Revenue
- 844.51
- Selling/ General/ Admin Expenses Total
- 151.68
- Depreciation/ Amortization
- 34.03
- Other Operating Expenses Total
- 196.08
- Total Operating Expense
- 655.42
- Operating Income
- 189.09
- Net Income Before Taxes
- 183.95
- Net Income
- 133.57
- Diluted Normalized EPS
- 8.46
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 881.74
- Selling/ General/ Admin Expenses Total
- 148.28
- Depreciation/ Amortization
- 32.17
- Other Operating Expenses Total
- 191.75
- Total Operating Expense
- 670.37
- Operating Income
- 211.37
- Net Income Before Taxes
- 208.66
- Net Income
- 150.59
- Diluted Normalized EPS
- 9.54
- Period
- 2023-09-30
- Total Assets
- 3799.2
- Total Liabilities
- 1082.49
- Total Equity
- 2716.71
- Tangible Book Valueper Share Common Eq
- 88.03
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 421.61
- Cashfrom Investing Activities
- -192.64
- Cashfrom Financing Activities
- -214.27
- Net Changein Cash
- 14.69
- Period
- 2023-06-30
- Total Revenue
- 896.2
- Selling/ General/ Admin Expenses Total
- 148.75
- Depreciation/ Amortization
- 31.38
- Other Operating Expenses Total
- 205.37
- Total Operating Expense
- 695.47
- Operating Income
- 200.73
- Net Income Before Taxes
- 194.3
- Net Income
- 142.32
- Diluted Normalized EPS
- 9.07
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 762.32
- Selling/ General/ Admin Expenses Total
- 135.63
- Depreciation/ Amortization
- 31.8
- Other Operating Expenses Total
- 188.19
- Total Operating Expense
- 630.48
- Operating Income
- 131.85
- Net Income Before Taxes
- 122.46
- Net Income
- 87.63
- Diluted Normalized EPS
- 5.56
- Period
- 2023-03-31
- Total Assets
- 3553.87
- Total Liabilities
- 1073.52
- Total Equity
- 2480.35
- Tangible Book Valueper Share Common Eq
- 71.12
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 625.61
- Cashfrom Investing Activities
- -961.79
- Cashfrom Financing Activities
- 356.54
- Net Changein Cash
- 20.39
- Period
- 2022-12-31
- Total Revenue
- 792.71
- Selling/ General/ Admin Expenses Total
- 138.33
- Depreciation/ Amortization
- 28.4
- Other Operating Expenses Total
- 180.6
- Total Operating Expense
- 646.34
- Operating Income
- 146.37
- Net Income Before Taxes
- 141.2
- Net Income
- 106.1
- Diluted Normalized EPS
- 6.78
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
JB Chemicals & Pharmaceuticals Technical
Moving Average
SMA
- 5 Day1729.78
- 10 Day1793.18
- 20 Day1848.21
- 50 Day1856.86
- 100 Day1857.53
- 300 Day1789.65
JB Chemicals & Pharmaceuticals Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Gland Pharma
- 1788.7
- 10.25
- 0.58
- 2220.95
- 1590
- 29461.77
- Laurus Labs
- 489.25
- 0.1
- 0.02
- 517.9
- 358.7
- 26368.9
- JB Chemicals & Pharmaceuticals
- 1715
- 49.1
- 2.95
- 2029
- 1376.95
- 26617.05
- Natco Pharma
- 1376.4
- 10.25
- 0.75
- 1638.35
- 752.55
- 24637.56
- Alembic Pharmaceuticals
- 1038.4
- -4.2
- -0.4
- 1296.15
- 710.5
- 20411.11
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Gland Pharma
- 38.03
- 3.37
- 14.89
- 22.92
- Laurus Labs
- 162.98
- 6.41
- 20.68
- 12.83
- JB Chemicals & Pharmaceuticals
- 47.82
- 8.85
- 20.54
- 16.06
- Natco Pharma
- 17.63
- 4.18
- 14.63
- 25.16
- Alembic Pharmaceuticals
- 33.3
- 4.24
- 15.94
- 12.47
JB Chemicals & Pharmaceuticals Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 06-Nov-24
- Quarterly Results
- 08-Aug-24
- Quarterly Results
- 17-May-24
- Audited Results & Final Dividend
- 06-Feb-24
- Quarterly Results & Interim Dividend
- 07-Nov-23
- Quarterly Results
- 09-Aug-23
- Quarterly Results
- 24-May-23
- Audited Results, Dividend & Stock Split
- 08-Feb-23
- Quarterly Results & Interim Dividend
- 11-Nov-22
- Quarterly Results
- 04-Aug-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 21-Aug-24
- 26-Jul-24
- AGM
- 07-Jul-24
- 05-Jun-24
- POM
- 09-Apr-24
- 11-Mar-24
- POM
- 22-Dec-23
- 20-Nov-23
- POM
- 24-Aug-23
- 28-Jul-23
- AGM
- 09-Sept-21
- 10-Aug-21
- AGM
- 02-Aug-21
- 02-Jul-21
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 17-May-24
- 14-Aug-24
- 14-Aug-24
- 6.75
- 06-Feb-24
- 16-Feb-24
- 16-Feb-24
- 5.5
- 29-May-23
- -
- 17-Aug-23
- 9.25
- 08-Feb-23
- 18-Feb-23
- 17-Feb-23
- 8.5
- 26-May-22
- -
- -
- 8
- 14-Feb-22
- 24-Feb-22
- 23-Feb-22
- 8.5
- 16-Jun-21
- -
- 01-Sept-21
- 8
- 10-Feb-21
- 22-Feb-21
- 18-Feb-21
- 8.5
- Ex-Splits
- Old FV
- New FV
- Description
- 18-Sept-23
- 2
- 1
- Stock split from Rs. 2/- to 1/-.